Savara (SVRA) Total Liabilities (2010 - 2026)
Savara's (SVRA) quarterly Total Liabilities came in at $45.6 million in Q1 2026, up 9.98% year-on-year from $41.5 million in Q1 2025, and down 9.34% on a QoQ basis from $50.3 million in Q4 2025.
Savara (SVRA) Total Liabilities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Total Liabilities data on file, last reported at $45.6 million in Q1 2026.
- On a quarterly basis, Total Liabilities rose 9.98% year-over-year to $45.6 million in Q1 2026; TTM through Mar 2026 was $45.6 million, a 9.98% increase from a year earlier, with the FY2025 full-year figure at $50.3 million, up 21.42% from the prior year.
- Total Liabilities for Q1 2026 stood at $45.6 million, down from $50.3 million in the prior quarter.
- Over the last five years, Total Liabilities for SVRA reached as high as $50.3 million in Q4 2025 and fell as low as $29.7 million in Q1 2022.
- Historically, Total Liabilities has averaged $37.7 million across 5 years, with a median of $37.2 million in 2023.
- Across the five-year window, Total Liabilities fell 8.54% in 2022 and rose 21.42% in 2025, its largest moves.
- Year by year, Total Liabilities stood at $32.0 million in 2022, then increased by 16.23% to $37.2 million in 2023, then advanced by 11.39% to $41.4 million in 2024, then advanced by 21.42% to $50.3 million in 2025, then dropped by 9.34% to $45.6 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $45.6 million in Q1 2026, $50.3 million in Q4 2025, and $46.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 177.22 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 7.33 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 753.82 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | 45.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.61 Mn |
| Dec 31, 2025 | 50.30 Mn |
| Sep 30, 2025 | 46.54 Mn |
| Jun 30, 2025 | 43.28 Mn |
| Mar 31, 2025 | 41.47 Mn |
| Dec 31, 2024 | 41.43 Mn |
| Sep 30, 2024 | 39.47 Mn |
| Jun 30, 2024 | 37.94 Mn |
| Mar 31, 2024 | 36.43 Mn |
| Dec 31, 2023 | 37.19 Mn |
| Sep 30, 2023 | 35.53 Mn |
| Jun 30, 2023 | 32.12 Mn |
| Mar 31, 2023 | 31.10 Mn |
| Dec 31, 2022 | 32.00 Mn |
| Sep 30, 2022 | 31.24 Mn |
| Jun 30, 2022 | 29.74 Mn |
| Mar 31, 2022 | 29.73 Mn |
| Dec 31, 2021 | 32.10 Mn |
| Sep 30, 2021 | 32.05 Mn |
| Jun 30, 2021 | 31.05 Mn |